On June 26, 2025, United Therapeutics Corporation's shareholders approved an amendment to their 2015 Stock Incentive Plan, increasing the maximum shares by 950,000 and extending the Plan's expiration to April 24, 2035. Key voting results included 36.9M votes for the amendment and 39.3M votes for the appointment of Ernst & Young as the auditor for 2025.